Advantage Alpha Capital Partners LP Invests $204,000 in Aurinia Pharmaceuticals Inc $AUPH

Advantage Alpha Capital Partners LP purchased a new stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,079 shares of the biotechnology company’s stock, valued at approximately $204,000.

Several other institutional investors have also added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $140,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Aurinia Pharmaceuticals by 24.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,641 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 8,390 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Aurinia Pharmaceuticals in the first quarter worth $86,000. Federated Hermes Inc. raised its stake in Aurinia Pharmaceuticals by 35.7% during the first quarter. Federated Hermes Inc. now owns 66,988 shares of the biotechnology company’s stock valued at $539,000 after purchasing an additional 17,629 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in Aurinia Pharmaceuticals by 656.2% during the first quarter. GSA Capital Partners LLP now owns 88,911 shares of the biotechnology company’s stock valued at $715,000 after purchasing an additional 77,153 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ AUPH opened at $16.20 on Friday. Aurinia Pharmaceuticals Inc has a 1-year low of $6.55 and a 1-year high of $16.48. The business has a fifty day moving average price of $13.25 and a 200 day moving average price of $10.95. The stock has a market capitalization of $2.14 billion, a P/E ratio of 37.68 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AUPH. Jefferies Financial Group raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $10.00 to $21.00 in a report on Friday, November 7th. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.67.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.